Natural Investments LLC Has $317,000 Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Natural Investments LLC has reduced its holdings in Gilead Sciences by 43.4%, holding $317,000 worth of stock after selling 2,201 shares in the 2nd quarter.
• CEO Daniel Patrick O'day sold 10,000 shares of Gilead at an average price of $111.66, which decreased his ownership by 1.66%.
• Analysts have given Gilead Sciences a consensus rating of "Moderate Buy" with an average price target of $118.08, following recent upgrades from multiple banks.

Natural Investments LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 43.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,865 shares of the biopharmaceutical company's stock after selling 2,201 shares during the quarter. Natural Investments LLC's holdings in Gilead Sciences were worth $317,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Vanguard Group Inc. boosted its position in Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after buying an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock valued at $1,541,302,000 after buying an additional 1,520,809 shares during the last quarter. Nuveen LLC bought a new position in Gilead Sciences in the 1st quarter valued at $620,415,000. Finally, Robeco Institutional Asset Management B.V. boosted its position in Gilead Sciences by 12.5% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company's stock valued at $414,948,000 after buying an additional 417,237 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. The trade was a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Royal Bank Of Canada increased their price objective on Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a research report on Wednesday. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Cantor Fitzgerald increased their price target on Gilead Sciences from $129.00 to $135.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $118.08.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $117.18 on Friday. The company has a market capitalization of $145.40 billion, a PE ratio of 23.34, a PEG ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock's fifty day simple moving average is $114.65 and its 200 day simple moving average is $110.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.